DailyIQ
|
Sector:HealthcareAll sectors
Last updated 1 minute ago

DXCM·DexCom, Inc.

$.
+. (+.%)
After Hours
High
$75.57
Open
$73.15
Market Cap
28.91B
52W High
$89.98
Low
$72.20
P. Close
$74.96
P/E
31.07
52W Low
$54.11
Fwd P/E
24.28
DailyIQ Est.
$90.46
Technical Score (1D)
95
BUY
News Sentiment
81
BULLISH
DexCom’s latest earnings report shows a 27 % jump in EPS and strong fundamentals, and technical analysis flags a breakout near $75.38, positioning the stock as a compelling growth play. The breakout suggests that short‑term buyers may see the current price as a support level, potentially driving a rally if the trend holds. Investor Day communications lifted sentiment among fund managers, which has already translated into a short‑term momentum boost for the shares. However, a Class II recall of certain G7 sensor lots introduces safety and accuracy concerns that could dampen sales in the near term. The recall’s impact on revenue will depend on how quickly the company resolves the issue and communicates the timeline to regulators and customers. Because the continuous glucose monitoring platform remains the core revenue driver, the market is weighing whether the current valuation reflects the potential upside once the recall is cleared. Over the next 1–10 trading days, traders should monitor the company’s guidance on recall resolution and any updates on regulatory reviews. Additionally, watch for any further analyst re‑ratings that may follow the recall news, as they could influence short‑term sentiment. Finally, keep an eye on the technical breakout near $75.38; if the stock fails to hold above this level, it could trigger a pullback that would test the recent bullish momentum.
Earnings Summary
DexCom, Inc. is a medical technology firm that specializes in continuous glucose monitoring (CGM) systems for diabetes management, offering integrated devices such as the Dexcom G6 and G7, along with ancillary products like Dexcom Share and the Real‑Time API, and expanding its portfolio with Dexcom ONE and Stelo to broaden access. Operating in the healthcare medical devices sector, DexCom has positioned itself as a key player in the growing CGM market, targeting endocrinologists, physicians, and diabetes educators through direct marketing. In the most recent two quarters, DexCom posted EPS of $0.68 in Q4 2025 and $0.56 in Q1 2026, both beating analyst estimates of $0.48 and $0.47 respectively, while revenue rose to $1.259 billion and $1.191 billion, surpassing estimates of $1.182 billion and $1.175 billion; however, revenue growth slowed from a $50 million increase in Q4 2025 versus Q3 2025 to a $68 million decline in Q1 2026 versus Q4 2025, and EPS growth decelerated from a $0.07 rise to a $0.12 decline. Historically, DexCom has maintained a strong YoY trajectory, with revenue up 13% in Q4 2025 versus Q4 2024 and 15% in Q1 2026 versus Q1 2025, and EPS surging 51% and 75% respectively, consistently beating estimates across all reported quarters, indicating robust profitability despite occasional revenue deceleration. Recent news highlights FDA clearance for the Stelo biosensor in children aged two and older, an upcoming July app launch linking glucose data to lifestyle factors, and analyst upgrades from Argus Research, Deutsche Bank, and Piper Sandler that underscore market optimism; these developments suggest potential acceleration in adoption, particularly in the non‑insulin type 2 diabetes segment, while also noting competitive pressure from GLP‑1 therapies. Investors should watch for the Q2 2026 earnings release to confirm revenue and margin guidance, regulatory updates on new product lines, adoption metrics for the expanded Stelo offering, quarterly type 2 CGM sales data, and any shifts in market share relative to Abbott, as these factors will be key to assessing whether DexCom’s growth thesis holds in the near term.

EPS

EstBeatMiss
$0.27$0.38$0.50$0.62$0.73Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$0.61 - -
Q1'26$0.47$0.56+19.0%
Q4'25$0.48$0.68+42.8%
Q3'25$0.57$0.61+7.5%
Q2'25$0.44$0.48+8.3%
Q1'25$0.33$0.32-2.6%

Revenue

EstBeatMiss
$994M$1.1B$1.2B$1.3B$1.4BQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$1.3B - -
Q1'26$1.2B$1.2B+1.5%
Q4'25$1.2B$1.3B+6.5%
Q3'25 - $1.2B -
Q2'25 - $1.2B -
Q1'25 - $1.0B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

DXCM Stock Snapshot

DXCM is currently trading at $74.95, giving DexCom, Inc. a market cap of 28.91B and a P/E ratio of 31.1. Today's range spans $72.20–$75.57, with shares opening at $73.15 and moving down $0.01 (0.0%) from the prior close. DailyIQ's technical score sits at 95/100 (BUY) with a news sentiment reading of 81/100.

Over the past year DXCM has traded between $54.11 and $89.98 - the current price is +38.5% off the 52-week low and -16.7% from the high. 40 analysts cover the stock with a Buy consensus and a mean 12-month target of $85.24 (range $65.00–$112.00), implying upside of +13.7%.

Dividend-paying Healthcare stocks at the large-cap level tend to attract a different buyer mix than pure growth names - and DXCM (28.91B market cap) with a BUY read (95/100) and bullish sentiment (81/100) benefits from both income-oriented and growth-oriented flows. The current P/E ratio stands at 31.1. Price: $74.95 (in the middle of its 52-week range in $54.11–$89.98). When technical momentum aligns with that dual-buyer base, the price path tends to be more durable than single-buyer-type momentum trades.

What makes DXCM's BUY setup (95/100) particularly actionable at 28.91B in Healthcare capitalization is the scale-to-move ratio: large enough to feature on institutional mandates but not so large that the percentage upside is already compressed by index inertia. At $74.95 (in the middle of its 52-week range in $54.11–$89.98), with sentiment running bullish at 81/100, the setup rewards conviction-sized positioning more than it does speculative small bets.